Structure Therapeutics Reports Breakthrough Weight-Loss Results for Oral GLP-1 Candidate Aleniglipron
Phase 2b and ACCESS II studies show up to 15.3% weight reduction with promising tolerability, positioning aleniglipron as a potential ...
Phase 2b and ACCESS II studies show up to 15.3% weight reduction with promising tolerability, positioning aleniglipron as a potential ...
© 2024 All Rights Reserved: STOXPO.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More
In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information
Do you really wish to opt-out?